Phase II NSCLC (NCT 00290355) | Results recMAGE-A3 + AS02B | |
---|---|---|
Primary endpoint | DFI | HR: 0.75 (95% CI: 0.46-1.23) recMAGE-A3 + AS02B vs . Placebo p = 0.127 in favor of MAGE-A3 ASCI |
Secondary endpoints | Safety | Well tolerated |
 | Humoral immune response | Response induced in > 98% patients |
 | Cellular immune response | Response induced in 41% patients |